Home  |  Contact

Cellosaurus GTL16R3 (CVCL_VS68)

[Text version]

Cell line name GTL16R3
Synonyms GTL16 R3
Accession CVCL_VS68
Resource Identification Initiative To cite this cell line use: GTL16R3 (RRID:CVCL_VS68)
Comments Population: Japanese.
Selected for resistance to: ChEBI; CHEBI:91425; 2-[4-[3-(6-quinolinylmethyl)-5-triazolo[4,5-b]pyrazinyl]-1-pyrazolyl]ethanol (PF-04217903).
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Sequence variations Gene fusion; HGNC; 1097; BRAF + HGNC; 30646; SND1; Name(s)=SND1-BRAF (PubMed=22745804).
Mutation; HGNC; 11998; TP53; Simple; p.Arg110Cys (c.328C>T); ClinVar=VCV000142206; Zygosity=Heterozygous (from parent cell line).
Disease Gastric adenocarcinoma (NCIt: C4004)
Derived from metastatic site: Liver.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_7668 (GTL-16)
Sex of cell Female
Age at sampling 62Y
Category Cancer cell line
Publications

PubMed=22745804; DOI=10.1371/journal.pone.0039653
Lee N.V., Lira M.E., Pavlicek A., Ye J., Buckman D., Bagrodia S., Srinivasa S.P., Zhao Y., Aparicio S., Rejto P.A., Christensen J.G., Ching K.A.
A novel SND1-BRAF fusion confers resistance to c-Met inhibitor PF-04217903 in GTL16 cells through MAPK activation.
PLoS ONE 7:E39653-E39653(2012)

Cross-references
Gene expression databases GEO; GSM686017
GEO; GSM686037
GEO; GSM686038
Other Wikidata; Q93935415
Polymorphism and mutation databases Progenetix; CVCL_VS68
Entry history
Entry creation25-Feb-2019
Last entry update20-May-2021
Version number7